Nivolumab +/− Varlilumab for Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as varlilumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot have received chemotherapy, targeted agents, or immunotherapy within 4 weeks before joining the trial. It's best to discuss your specific medications with the trial team.
Is the combination of Nivolumab and Varlilumab safe for humans?
How is the drug Nivolumab unique in treating lymphoma?
Nivolumab is unique because it is a PD-1 inhibitor that helps the immune system recognize and attack cancer cells, and it is specifically approved for use in Hodgkin lymphoma that has relapsed or progressed after other treatments. This makes it different from traditional chemotherapy, as it targets the immune system rather than directly attacking cancer cells.678910
What data supports the effectiveness of the drug Nivolumab for treating lymphoma?
Who Is on the Research Team?
Stephen M Ansell
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO
Are You a Good Fit for This Trial?
This trial is for adults with aggressive B-cell non-Hodgkin lymphoma that has returned or resisted treatment after two standard therapies. Participants must have a life expectancy over 12 weeks, measurable disease, good physical function (ECOG 0-1), and adequate blood counts and organ function. Pregnant or breastfeeding women, those with severe allergies to similar drugs, uncontrolled illnesses, certain autoimmune diseases, recent immunosuppressants use or other cancers being treated within the last three years are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive nivolumab and/or varlilumab intravenously over a period of up to 2 years, with varying schedules based on group assignment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nivolumab
- Varlilumab
Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor